Table 1.
Pooled results from currently presented and previously reported cases.
| Initial Treatment DBS (n = 70) | Initial Treatment CLI (n = 15) | |
|---|---|---|
| Sex F (n out of total n; (%)) | 27/61 (44%) | 1/12 (8%) |
| Age at PD diagnosis in years; WM (range, n) | 47 (30–70, n = 57) | 49 (29–64, n = 13) |
| Age at initiation of initial treatment in years; WM (range, n) | 60 (40–77, n = 38) | 57 (47–67, n = 13) |
| Beneficial effect of initial treatment (n out of total n; (%)) | 32/40 (80%) | 10/12 (83%) |
| Major indication for 2nd treatment (more than one possible) | ||
| MFD (n out of total n; (%)) | 45/59 (76%) | 14/15 (93%) |
| GI/FOG (n out of total n; (%)) | 14/59 (24%) | 2/15 (13%) |
| Interval between treatment in years; WM (range, n) | 6.9 (0–18, n = 57) | 4.2 (2–9, n = 13) |
| Beneficial effect of second treatment (n out of total n; (%)) | 60/64 (94%) | 10/12 (83%) |
| DBS target | ||
| STN | 87% | 87% |
| GPi | 10% | 13% |
| PPN | 3% | 0% |
CLI: Continuous levodopa/carbidopa infusion; DBS: deep brain stimulation; GI: gait impairment; F: female; FOG: freezing of gait; GPi: globus pallidus interna; M: male; MFD: unpredictable motor fluctuations and dyskinesias; PD: Parkinson’s disease; PPN: pedunculopontine nucleus; STN: subthalamic nucleus; WM: weighted mean.